Original Research
Accepted on 18 Aug 2025
Ramucirumab plus paclitaxel as switch maintenance in patients with advanced HER2-negative gastric or gastro-oesophageal junction cancer: a cost-effectiveness analysis
in Gastrointestinal and Hepatic Pharmacology